Croucher P - Search Results

1

Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo.

Xu S, De Veirman K, Evans H, Santini GC, Vande Broek I, Leleu X, De Becker A, Van Camp B, Croucher P, Vanderkerken K, Van Riet I. Xu S, et al. Among authors: croucher p. Acta Pharmacol Sin. 2013 May;34(5):699-709. doi: 10.1038/aps.2012.182. Epub 2013 Apr 8. Acta Pharmacol Sin. 2013. PMID: 23564084 Free PMC article.

2

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.

Shipman CM, Vanderkerken K, Rogers MJ, Lippitt JM, Asosingh K, Hughes DE, Van Camp B, Russell RG, Croucher PI. Shipman CM, et al. Among authors: croucher pi. Br J Haematol. 2000 Oct;111(1):283-6. doi: 10.1046/j.1365-2141.2000.02310.x. Br J Haematol. 2000. PMID: 11091214 Free article.

3

Bisphosphonates--mechanisms of action in multiple myeloma.

Shipman CM, Rogers MJ, Vanderkerken K, Van Camp B, Graham R, Russell G, Croucher PI. Shipman CM, et al. Among authors: croucher pi. Acta Oncol. 2000;39(7):829-35. doi: 10.1080/028418600750063587. Acta Oncol. 2000. PMID: 11145441

4

In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells.

Asosingh K, De Raeve H, Croucher P, Goes E, Van Riet I, Van Camp B, Vanderkerken K. Asosingh K, et al. Among authors: croucher p. Exp Hematol. 2001 Jan;29(1):77-84. doi: 10.1016/s0301-472x(00)00625-1. Exp Hematol. 2001. PMID: 11164108 Free article.

5

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJ, Holen I, Skerry TM, Dunstan CR, Russell GR, Van Camp B, Vanderkerken K. Croucher PI, et al. Blood. 2001 Dec 15;98(13):3534-40. doi: 10.1182/blood.v98.13.3534. Blood. 2001. PMID: 11739154 Free article.

6

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B, Croucher P. Vanderkerken K, et al. Among authors: croucher p. Cancer Res. 2003 Jan 15;63(2):287-9. Cancer Res. 2003. PMID: 12543775

7

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.

Croucher PI, Shipman CM, Van Camp B, Vanderkerken K. Croucher PI, et al. Cancer. 2003 Feb 1;97(3 Suppl):818-24. doi: 10.1002/cncr.11125. Cancer. 2003. PMID: 12548581 Free article.

8

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B, Vanderkerken K. Croucher PI, et al. J Bone Miner Res. 2003 Mar;18(3):482-92. doi: 10.1359/jbmr.2003.18.3.482. J Bone Miner Res. 2003. PMID: 12619933 Free article.

9

Multiple myeloma biology: lessons from the 5TMM models.

Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Vanderkerken K, et al. Among authors: croucher p. Immunol Rev. 2003 Aug;194:196-206. doi: 10.1034/j.1600-065x.2003.00035.x. Immunol Rev. 2003. PMID: 12846816 Review.

10

Evidence of a role for RANKL in the development of myeloma bone disease.

De Leenheer E, Mueller GS, Vanderkerken K, Croucher PI. De Leenheer E, et al. Curr Opin Pharmacol. 2004 Aug;4(4):340-6. doi: 10.1016/j.coph.2004.03.011. Curr Opin Pharmacol. 2004. PMID: 15251126 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

231 results

Search Page

Filters